Viridian Therapeutics (0K1R.L) Stock Price

$15.52 5.7%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    5

  • Fundamental

    6

  • Technical

    6

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Viridian Therapeutics, AI stock picks, stock alerts and much more.

Sign up

0K1R.L AI Stock Analysis

AI stock analysis for 0K1R.L is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Viridian Therapeutics (0K1R.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Viridian Therapeutics (0K1R.L) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Viridian Therapeutics (0K1R.L), currently trading at $15.52, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About 0K1R.L

LSE

  • Viridian Therapeutics, Inc.

  • Symbol

    0K1R.L

  • Market

    LSE

  • Industry

    Biotechnology

  • Market Cap

    1.3B

Similar Stocks

0I0X.L Codexis
0I0X.L		 $2.7
8%
4
ONT.L Oxford Nanopore Technologies plc
ONT.L		 £142
2.2%
6
SAR.L Sareum Holdings
SAR.L		 £19.5
5.4%
6
AVCT.L Avacta Group Plc
AVCT.L		 £30.5
0.00%
2
IMM.L ImmuPharma
IMM.L		 £2.18
1.8%
5

News

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
April 21, 2025. GlobeNewswire
Geode Capital Management LLC Purchases 165,669 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Geode Capital Management LLC Purchases 165,669 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)
April 17, 2025. ETF Daily News
Thyroid Eye Disease Treatment Market Forecast to Reach $11.81 Billion by 2031 | Emerging Economies Expand Access to Thyroid Eye Disease Diagnoses and Therapies

Thyroid Eye Disease Treatment Market Forecast to Reach $11.81 Billion by 2031 | Emerging Economies Expand Access to Thyroid Eye Disease Diagnoses and Therapies
April 16, 2025. GlobeNewswire
ExodusPoint Capital Management LP Takes $493,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

ExodusPoint Capital Management LP Takes $493,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)
April 13, 2025. ETF Daily News

0K1R.L Alternative Data

Web Traffic

Viridian Therapeutics receives an estimated 6276 monthly visitors to viridiantherapeutics.com.

  • Web Traffic

    6276

  • Change from Previous Month

    12.4%

  • 3 Month Change

    68.3%

  • YoY Change

    68.3%

Twitter Followers

Viridian Therapeutics has 819 Twitter Followers on its main Twitter (also known as X) account.

  • Twitter Followers

    819

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Instagram Followers

Viridian Therapeutics has 642 Instagram Followers on its main Instagram account, up by 0.8% over the last month.

  • Instagram Followers

    642

  • Daily Change

    0.2%

  • 1 Month Change

    0.8%

  • 3 Month Change

    2.4%

Job Postings

Viridian Therapeutics currenly has an estimated 12 open job postings, up by 20% over the last month.

  • Job Postings

    12

  • Daily Change

    20%

  • 1 Month Change

    20%

  • 3 Month Change

    7.7%

Reddit Mentions

Viridian Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

LinkedIn Followers

15,129 are following Viridian Therapeutics on LinkedIn, up by 4.8% over the last month.

  • LinkedIn Followers

    15129

  • Daily Change

    4.8%

  • 1 Month Change

    4.8%

  • 3 Month Change

    10.2%

Business Outlook

According to employee reviews, the business outlook among employees at Viridian Therapeutics is 57 out of 100 (neutral).

  • Business Outlook

    57

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

LinkedIn Employees

According to LinkedIn, Viridian Therapeutics has 211 employees, up by 3.9% over the last month.

  • LinkedIn Employees

    211

  • Daily Change

    3.9%

  • 1 Month Change

    3.9%

  • 3 Month Change

    13.4%

News Mentions

Viridian Therapeutics was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

0K1R.L Financials

0K1R.L Key Metrics

  • Total Revenue

    $72K

  • Net Income

    -$86.9M

  • Earnings per Share

    -$0.87

  • Free cash flow

    -$92.7M

  • EBITDA

    -$86.2M

  • EBITDA Ratio

    -1197.35

  • Total Assets

    $661M

0K1R.L 2-year Revenue & Income
0K1R.L 2-year Free Cash Flow

0K1R.L Technicals

0K1R.L SMA
0K1R.L RSI

FAQ

What's the current price of Viridian Therapeutics (0K1R.L) Stock?
The price of an Viridian Therapeutics (0K1R.L) share is $15.52.

What's the market cap of Viridian Therapeutics?
The current market cap of Viridian Therapeutics is 1.3B.

Should I buy or sell 0K1R.L?
Viridian Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Viridian Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.

Is Viridian Therapeutics a good investment?
The current analysis of Viridian Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Viridian Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Viridian Therapeutics (0K1R.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Viridian Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Viridian Therapeutics (0K1R.L) that investors often compare it to?
Viridian Therapeutics (0K1R.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Avacta Group Plc and ImmuPharma.

What is the forecast for Viridian Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Viridian Therapeutics' stock price to be around $15.71 in 2026. Starting from the current price of $15.52, this represents a 1.3% change in price, indicating a neutral outlook for the stock.

How to buy Viridian Therapeutics (0K1R.L) Stock?
Viridian Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Viridian Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.